BOTOX® Treatment in Pediatric Upper Limb Spasticity

Study ID

Cancer Related

Healthy Volunteers

Study Sites

  • Children’s Medical Center (Dallas, Plano, Southlake)

Kara Lorduy

Principal Investigator
Fatma Gul, M.D.

Official Title

BOTOX® Treatment in Pediatric Upper Limb Spasticity: Double-blind Study

Brief Overview

This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) in
pediatric patients with upper limb spasticity.

Participant Eligibility

Inclusion Criteria:

- Minimum weight of 10 kg/22 lb

- Upper limb spasticity due to cerebral palsy or stroke

Exclusion Criteria:

- Muscular dystrophy, myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral
sclerosis, or mitochondrial disease

- Uncontrolled epilepsy

- Botulinum Toxin therapy of any serotype for any condition within the last 6 months

- Previous surgical treatment of the study limb (except tendon lengthening), or planned
surgery of the study limb during the study

- Previous casting of the study limb for spasticity within 6 months or with a dynamic
splint within 3 months, or planned casting or dynamic splinting for spasticity of the
study limb or affected lower limb during the study